Over the past few months, we’ve read no shortage of analyses about why prescription drugs cost what they do. Some are thoughtful and grounded in the realities of biomedical innovation. But too many rely on simplistic narratives that sound compelling — yet fall apart under scrutiny.
One of the most common examples is the claim that high drug prices are driven by so-called “patent thickets.” Commentators (including in this piece) often point to specific drugs with a large number of patents. The implication is that companies are merely “layering” patents to block competition.
That interpretation misses something fundamental: much of what gets labeled a “patent thicket” is actually the result of post-approval R&D — the ongoing work required to improve medicines after they first reach patients.
In biotech, the FDA approval is rarely the end of the story. Companies continue investing to make therapies safer, more effective, easier to administer, and better suited for real-world use. Improvements like new formulations, more convenient dosing schedules, or improved injector devices are not trivial. They can meaningfully reduce side effects, increase adherence, and improve quality of life for patients.
And this kind of follow-on innovation isn’t unique to pharmaceuticals. It’s how progress works in nearly every high-tech industry. No one argues that Apple is “gaming” the system when it patents improved iPhone batteries, cameras, or biometric features year after year. Automakers patent new safety technologies and fuel-efficiency advances across generations of vehicles. Innovation is iterative — and the patent system is designed to reward those continuing advances.
The same principle applies in medicine. Calling post-approval R&D a “thicket” obscures the reality that these patents often reflect real scientific and engineering progress, not legal trickery.
We must get the innovation story right and move beyond myths that treat all subsequent patents as suspect.
To learn more about the misconception around “patent thickets,” you can watch this short video from our friends at the Council for Innovation Promotion.